help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. suppl_2, 4-7, April 2008; doi:10.1634/theoncologist.13-S2-4
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Choi, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, H.

Response Evaluation of Gastrointestinal Stromal Tumors

Haesun Choi

University of Texas, M. D. Anderson Cancer Center, Houston, Texas, USA

Key Words. Gastrointestinal stromal tumors • Response evaluation • Computed tomography

Correspondence: Correspondence: Haesun Choi, M.D., University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 57, Houston Texas 77030, USA. Telephone: 713-792-8177; Fax: 713-745-1302; e-mail: hchoi{at}di.mdacc.tmc.edu

Disclosure: No potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article.

Clinical management of patients with gastrointestinal stromal tumors (GISTs) has dramatically changed with the introduction of novel therapeutics, such as imatinib mesylate. This has created a need to re-evaluate the existing criteria used to assess treatment response. The current Response Evaluation Criteria in Solid Tumors are based on unidimensional tumor size, and do not take into account changes in responding GISTs such as a decrease in tumor density and decrease in the number of intratumoral vessels with computed tomography (CT). Positron emission tomography (PET) has been found to be highly sensitive in detecting early response, and to be useful in predicting long-term response to imatinib in patients with metastatic GIST; however, widespread use of PET is limited because of a lack of scanner availability and cost constraints. Modified CT criteria using a combination of tumor density and tumor size are promising in early response evaluation, and have excellent prognostic value. Identifying appropriate treatment response criteria is essential to optimize treatment for patients with GIST.




This article has been cited by other articles:


Home page
 The OncologistHome page
A. D. Van den Abbeele
The Lessons of GIST--PET and PET/CT: A New Paradigm for Imaging
Oncologist, April 1, 2008; 13(suppl_2): 8 - 13.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. C. Jaffe
Response Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design
Oncologist, April 1, 2008; 13(suppl_2): 14 - 18.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2008 by AlphaMed Press.